Peptide Library

Human study PLS-00119

The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.

Other design · Not reported participants enrolled · not included in the assessments (not human)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.primary · Scientific reports · 2018-10-26 · PMID 30367115 · DOI

Design and participants

Design
Other design
Population
51 patients with type 2 diabetes and 57 controls who provided leukocytes for ex vivo experiments
Conditions
Type 2 diabetes mellitus
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors concluded that SS-31 benefits leukocytes from type 2 diabetes patients. It reduced oxidative stress, leukocyte-endothelium interactions, NFκB and TNFα, and raised SIRT1, which they say supports its potential use against cardiovascular risk.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: SS-31 was applied to isolated leukocytes in vitro, not administered to patients, so no clinical effect can be inferred.
    • inappropriate endpoint: Only cellular biomarkers (mitochondrial ROS, membrane potential, glutathione, SIRT1, NFκB, TNFα, adhesion) were measured.
    • abstract only: Only the PubMed abstract is available in the record, with no numerical results or methods detail.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 30367115, abstract (sentences 9-10) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 30367115, abstract (sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 30367115, abstract (sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 30367115, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 30367115, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).